Brief: Huakang Biomedical Sees Loss Attributable Of About RMB4.2 Million For Year
04/03/2022 10:31
March 4 (Reuters) - Huakang Biomedical Holdings Co Ltd
8622.HK :
* SEES LOSS ATTRIBUTABLE TO OWNERS OF APPROXIMATELY RMB4.2
MILLION
FOR YEAR
* EXPECTED RESULT DUE TO A INCREASE IN GROUP'S GROSS PROFIT
OF
APPROXIMATELY RMB1.7 MILLION FOR CURRENT YEAR, AMONG OTHERS
Source text for Eikon: ID:nHKS1Wqmhc
Further company coverage: 8622.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Joyzyme
See all newsChairman
Brief: Huakang Biomedical Trading In Co's Shares Halted
Brief: Huakang Biomedical Says Zhang Shuguang Resigns As Executive Director And Chairman
Brief: Huakang Biomedical Announces Zhang Yujing Appointed As Executive Director
Brief: Huakang Biomedical To Acquire 51% Interest In Hunan Keyue Biotechnology